The abstract is read at the publisher; the summary is JClub's.
Single-dose PHP.eB scAAV encoding Exendin-4 (Ex4) or Ex4-Fc reduced body weight in diet-induced obese mice by up to 22.6% through 21 days.
- Why it matters: Durable GLP-1R agonist exposure from one AAV dose could replace chronic adherence, but it is unclear how peptide sequence engineering affects in vivo efficacy.
- What they did: Four PHP.eB scAAV constructs (GLP-1, Gly8, Ex4, Ex4-Fc) were validated by conditioned-media potency assays, then given intravenously at 5x1012 vg/kg to DIO mice; weight, food intake, insulin, and oral glucose tolerance were tracked for 3 weeks.
- The result: Ex4 and Ex4-Fc, but not GLP-1 or Gly8, lowered food intake, fat mass, and fasting insulin versus vehicle, improved oral glucose tolerance, and reduced plasma cholesterol and liver triglycerides; peptide levels in plasma/brain matched the in vitro potency rank order.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.